Literature DB >> 17962752

Synthetic studies on erythromycin derivatives: reactivity of the C12-21 alkene.

Wei-Min Chen1.   

Abstract

The reactivity of the C12-21 alkene of some erythromycin A derivatives was studied. This double bond was easily oxidized to the corresponding epoxide with excellent stereoselectivity. A single crystal X-ray structure showed that the epoxide moiety was on the same side as the acetonide. When an erythromycin derivative containing a C12-21 alkene was treated with diazomethane a [3+2] cycloaddition affording a pyrazoline occurred. In the case of 6-O-allylated erythromycin derivatives the C12-21 alkene was selectively epoxidized in the presence of the 6-O-allyl moiety. These results show that the C12-21 alkene is an active reaction site, which can be used for useful further modification of erythromycin derivatives.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17962752      PMCID: PMC6148660          DOI: 10.3390/11010121

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  4 in total

1.  Synthesis and activity of C-21 alkylamino derivatives of (9R)-erythromycylamine.

Authors:  P A Lartey; S L DeNinno; R Faghih; D J Hardy; J J Clement; J J Plattner
Journal:  J Antibiot (Tokyo)       Date:  1992-03       Impact factor: 2.649

2.  Convergent synthesis and antibacterial activity of pyrazole and pyrazoline derivatives of diazepam.

Authors:  Moged A Berghot; Evelin B Moawad
Journal:  Eur J Pharm Sci       Date:  2003-10       Impact factor: 4.384

3.  Zirconium-catalyzed enantioselective [3+2] cycloaddition of hydrazones to olefins leading to optically active pyrazolidine, pyrazoline, and 1,3-diamine derivatives.

Authors:  Yasuhiro Yamashita; Shū Kobayashi
Journal:  J Am Chem Soc       Date:  2004-09-15       Impact factor: 15.419

4.  1-N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation as MAO inhibitors.

Authors:  Nesrin Gökhan; Akgül Yeşilada; Gülberk Uçar; Kevser Erol; A Altan Bilgin
Journal:  Arch Pharm (Weinheim)       Date:  2003-08       Impact factor: 3.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.